RefDoc
Haut

Faire une nouvelle recherche
Make a new search
Lancer la recherche


Titre du document / Document title

Radioimmunoscintigraphy (RIS) with Bectumomab (Tc99m labeled IMMU-LL2, Lymphoscan®) in the assessment of recurrent non-Hodgkin's lymphoma (NHL)

Auteur(s) / Author(s)

LAMONICA D. (1) ; CZUCZMAN M. (1) ; NABI H. (1) ; KLIPPENSTEIN D. (1) ; GROSSMAN Z. (1) ;

Affiliation(s) du ou des auteurs / Author(s) Affiliation(s)

(1) Nuclear Medicine Section, Division of Diagnostic Imaging, Roswell Park Cancer Institute, S.U.N.Y. at Buffalo, Buffalo, NY, ETATS-UNIS

Résumé / Abstract

The efficacy of a Tc99m-labeled anti-lymphoma antibody fragment, bectumomab [LymphoScan®], was retrospectively examined in the staging of recurrent or newly diagnosed non-Hodgkin's lymphoma (NHL) [7 patients] and to assess targeting before radioimmunotherapy (RIT) [14 patients]. Performance was graded relative to conventional imaging. Tumors included 7 low-grade, 11 intermediate-grade, and 3 high-grade histologic subtypes. Computed x-ray tomography, radiogallium imaging, FDG-PET, and bone marrow biopsy defined 117 sites. Bectumomab revealed 56% of these sites. In 4 patients bectumomab uncovered five sites not evident by conventional imaging. In addition, it uncovered one site in the brain, an area not covered in the standard work-up of asymptomatic patients. Bectumomab imaging most often failed in central abdominal and thoracic locations, and excelled in revealing disease in the head and neck. Relative to Ga67 citrate imaging, the performance of bectumomab was variable, with no clear relation to anatomic location; there was better targeting of low and intermediate grade NHL. Radiogallium out-performed bectumomab imaging in 23 sites, 19 of which were in patients with high or intermediate-grade disease. Bectumomab was superior to radiogallium at six sites, five of which involved low-grade tumor. Conclusion: Bectumomab shows promise as a pre-RIT probe for targeting of B-cell NHL. It excelled at defining small volume, low-grade disease. However, as a purely diagnostic agent, its performance was variable.

Revue / Journal Title

Cancer biotherapy & radiopharmaceuticals    ISSN  1084-9785   CODEN CBRAFJ 

Source / Source

2002, vol. 17, no6, pp. 689-697 [9 page(s) (article)] (11 ref.)

Langue / Language

Anglais

Editeur / Publisher

Liebert, New Rochelle, NY, ETATS-UNIS  (1996) (Revue)

Mots-clés anglais / English Keywords

Lymphoproliferative syndrome

;

Malignant hemopathy

;

Radionuclide study

;

Targeting

;

Clinical stage

;

Diagnostic agent

;

Monoclonal antibody

;

Single photon emission tomography

;

Medical imagery

;

Relapse

;

Non Hodgkin lymphoma

;

Human

;

Bectumomab

;

Mots-clés français / French Keywords

Lymphoprolifératif syndrome

;

Hémopathie maligne

;

Exploration radioisotopique

;

Ciblage

;

Stade clinique

;

Produit diagnostic

;

Anticorps monoclonal

;

Tomoscintigraphie émission monophotonique

;

Imagerie médicale

;

Récidive

;

Lymphome non hodgkinien

;

Homme

;

Bectumomab

;

Mots-clés espagnols / Spanish Keywords

Linfoproliferativo síndrome

;

Hemopatía maligna

;

Exploración radioisotópica

;

Blancado

;

Estadio clínico

;

Producto diagnóstico

;

Anticuerpo monoclonal

;

Tomografía emisión fotón único

;

Imaginería médica

;

Recaida

;

Linfoma no Hodgkin

;

Hombre

;

Bectumomab

;

Mots-clés d'auteur / Author Keywords

RAID

;

nuclear oncology

;

LL2

;

SPECT

;

immunoscintigraphy

;

emission tomography

;

Localisation / Location

INIST-CNRS, Cote INIST : 20609, 35400010364876.0100

Nº notice refdoc (ud4) : 14422885



Faire une nouvelle recherche
Make a new search
Lancer la recherche
Bas